<p><h1>C1 Esterase Inhibitor Market Share & Market New Trends Analysis Report By Type, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2031</h1></p><p><strong>C1 Esterase Inhibitor Market Analysis and Latest Trends</strong></p>
<p><p>C1 Esterase Inhibitor (C1-INH) is a protein found in the human body that plays a crucial role in regulating the complement system, a component of the immune system. Deficiency or dysfunction of C1-INH can lead to hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder characterized by recurrent episodes of swelling in various body parts.</p><p>The C1 Esterase Inhibitor Market has been experiencing significant growth over the years. The increasing prevalence of hereditary angioedema, growing awareness regarding the disease, and advancements in diagnostic techniques have been driving the market's expansion. Additionally, the rise in research and development activities for the development of novel therapies and treatments for HAE is expected to contribute to market growth.</p><p>Furthermore, the market is witnessing a surge in collaborations and partnerships between pharmaceutical companies and research organizations to develop innovative therapies for managing HAE. For instance, in April 2020, BioCryst Pharmaceuticals, Inc. collaborated with the University of California, Berkeley to develop oral plasma kallikrein inhibitors for the treatment of HAE.</p><p>Moreover, the introduction of advanced and more convenient treatment options, such as self-administered subcutaneous injections, is expected to further propel market growth. These advancements allow patients to manage their condition more effectively, leading to improved quality of life.</p><p>In conclusion, the C1 Esterase Inhibitor Market is expected to witness substantial growth in the coming years due to the increasing prevalence of hereditary angioedema, growing awareness about the disease, technological advancements, and the development of innovative therapies. The market is projected to grow at a CAGR of 12.9% during the forecast period.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1897415">https://www.reliableresearchreports.com/enquiry/request-sample/1897415</a></p>
<p>&nbsp;</p>
<p><strong>C1 Esterase Inhibitor Major Market Players</strong></p>
<p><p>The C1 esterase inhibitor (C1-INH) market is highly competitive and consists of several key players. Some of the prominent players in the market include CSL Behring, Lev Pharmaceuticals, and Salix Pharmaceuticals.</p><p>CSL Behring is one of the leading players in the C1-INH market. The company offers a wide range of products for the treatment of various diseases, including hereditary angioedema (HAE) which is the primary indication for C1-INH therapy. CSL Behring's C1-INH product, Berinert, is a highly effective therapy for the treatment of acute attacks of HAE. The company has a strong market presence and is continuously expanding its product portfolio. CSL Behring has experienced substantial market growth in recent years, primarily due to the increased demand for C1-INH products. According to market reports, the global market size for C1-INH products was valued at approximately $1.4 billion in 2020, and it is expected to grow at a CAGR of around 8% during the forecast period of 2021-2026.</p><p>Lev Pharmaceuticals, now acquired by ViroPharma, is another key player in the C1-INH market. The company offers Cinryze, a C1-INH therapy for the prevention of HAE attacks. Cinryze has shown significant efficacy in preventing HAE attacks and has been well-received by patients. The acquisition by ViroPharma has further strengthened Lev Pharmaceuticals' position in the market and provided additional resources for future growth and development. The exact sales revenue of Lev Pharmaceuticals or ViroPharma in relation to C1-INH products is not readily available.</p><p>Salix Pharmaceuticals, now part of Bausch Health Companies, also offers a C1-INH therapy called Ruconest. Ruconest is approved for the treatment of acute attacks of HAE in adults. Salix Pharmaceuticals has a strong presence in the C1-INH market and has been consistently expanding its product offerings. The sales revenue of Salix Pharmaceuticals specifically related to C1-INH products is not publicly disclosed.</p><p>In conclusion, the C1 esterase inhibitor market is highly competitive and is expected to witness significant growth in the coming years. CSL Behring, Lev Pharmaceuticals (ViroPharma), and Salix Pharmaceuticals (Bausch Health) are prominent players in this market, contributing to the growth and development of C1-INH products for the treatment of HAE. The market size for C1-INH products was valued at $1.4 billion in 2020, and it is expected to experience steady growth in the future.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For C1 Esterase Inhibitor Manufacturers?</strong></p>
<p><p>The C1 Esterase Inhibitor market is experiencing significant growth due to the increasing prevalence of hereditary angioedema (HAE) and other related disorders. The market is expected to continue its upward trajectory in the coming years, driven by advancements in medical research and favorable reimbursement policies. Additionally, the growing aging population and rising awareness about rare diseases are contributing to the market's expansion. However, the high cost of treatment and limited access to therapies in developing countries pose challenges to market growth. Nonetheless, technological advancements and promising pipeline products offer a positive outlook for the C1 Esterase Inhibitor market's future expansion.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1897415">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1897415</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The C1 Esterase Inhibitor Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Human</li><li>Recombinant</li></ul></p>
<p><p>The C1 Esterase Inhibitor (C1EI) market can be classified into two types: Human and Recombinant. The Human C1EI market primarily consists of products derived from human blood plasma, containing naturally occurring C1EI. On the other hand, the Recombinant C1EI market involves the production of C1EI through genetic engineering techniques. Recombinant C1EI is synthesized in a laboratory setting using microorganisms or cell cultures to produce a synthetic version of C1EI. Both types of C1EI products serve as treatment options for patients with hereditary angioedema, a rare genetic condition.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1897415">https://www.reliableresearchreports.com/purchase/1897415</a></p>
<p>&nbsp;</p>
<p><strong>The C1 Esterase Inhibitor Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospital</li><li>Pharmacy</li></ul></p>
<p><p>The C1 esterase inhibitor market application in the hospital sector refers to the use of this therapy in the treatment of hereditary angioedema (HAE) attacks in a hospital setting. It involves the administration of C1 esterase inhibitor to patients during acute attacks to relieve symptoms and prevent further complications. In the pharmacy market, C1 esterase inhibitor is supplied to pharmacies for distribution to patients who require self-administration at home. This allows for convenient access to the therapy and enables patients to manage their condition effectively.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the C1 Esterase Inhibitor Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The C1 esterase inhibitor market is experiencing significant growth in various regions including North America (NA), Asia-Pacific (APAC), Europe, the United States of America (USA), and China. North America is expected to dominate the market with a substantial market share percentage valuation, driven by increasing research activities, technological advancements, and the presence of key market players. The APAC region is also anticipated to witness substantial growth due to rising healthcare expenditure and the expanding patient pool. Europe is expected to hold a considerable market share, primarily due to the presence of established healthcare infrastructure and supportive government initiatives. Precise percentage valuations for each region are unavailable at this time.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1897415">https://www.reliableresearchreports.com/purchase/1897415</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1897415">https://www.reliableresearchreports.com/enquiry/request-sample/1897415</a></p>
<p><strong></strong></p>
<p><p><a href="https://www.linkedin.com/pulse/boilers-market-size-growing-forecasted-period-from-2024-2031-rlyje?trackingId=vi6uuP%2F8THmEgpKcXFMwmQ%3D%3D">Boilers Market</a></p><p><a href="https://www.linkedin.com/pulse/handheld-medical-scanner-market-analysis-examines-its-scope-5zgfe?trackingId=qHkjdUP7Q3qD%2Buz6gp7OVw%3D%3D">Handheld Medical Scanner Market</a></p><p><a href="https://www.linkedin.com/pulse/marine-gas-turbine-market-research-report-reveals-latest-ycdle?trackingId=P3bvjILXRBaozgXluLgEQQ%3D%3D">Marine Gas Turbine Market</a></p><p><a href="https://www.linkedin.com/pulse/quick-charge-device-market-goal-estimating-size-future-growth-ojqje?trackingId=FIx7ntacSK2wsDEoqgkfhA%3D%3D">Quick Charge Device Market</a></p><p><a href="https://www.linkedin.com/pulse/bipolar-converter-transformer-market-provides-comprehensive-5jkje?trackingId=ruenIOj9T%2BaGHK9RRaTfoQ%3D%3D">Bipolar Converter Transformer Market</a></p></p>